Tempest Therapeutics Future Growth

Future criteria checks 0/6

Tempest Therapeutics's earnings are forecast to decline at 14.5% per annum while its annual revenue is expected to grow at 66.9% per year. EPS is expected to grow by 6.5% per annum.

Key information

-14.5%

Earnings growth rate

6.5%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	66.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	20 Nov 2024

Recent future growth updates

Recent updates

Tempest Therapeutics GAAP EPS of -$0.79

Aug 15

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Jan 04

Earnings and Revenue Growth Forecasts

NasdaqCM:TPST - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-62	N/A	-52	4
12/31/2025	N/A	-47	N/A	-37	5
12/31/2024	N/A	-38	N/A	-33	5
9/30/2024	N/A	-36	-29	-29	N/A
6/30/2024	N/A	-32	-26	-25	N/A
3/31/2024	N/A	-30	-27	-26	N/A
12/31/2023	N/A	-29	-28	-27	N/A
9/30/2023	N/A	-31	-28	-28	N/A
6/30/2023	N/A	-33	-31	-30	N/A
3/31/2023	N/A	-35	-33	-32	N/A
12/31/2022	N/A	-36	-32	-31	N/A
9/30/2022	N/A	-34	-33	-33	N/A
6/30/2022	N/A	-34	-35	-35	N/A
3/31/2022	N/A	-31	-27	-27	N/A
12/31/2021	N/A	-28	-26	-26	N/A
9/30/2021	N/A	-25	-22	-22	N/A
6/30/2021	N/A	-22	-15	-15	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-19	-19	-19	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TPST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TPST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TPST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TPST is forecast to have no revenue next year.

High Growth Revenue: TPST is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TPST's Return on Equity is forecast to be high in 3 years time

Tempest Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 26% to US$19.67

Price target decreased by 18% to US$15.67

Price target increased by 16% to US$19.00

Recent updates

New major risk - Shareholder dilution

New major risk - Financial position

Tempest Therapeutics, Inc. Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

Insufficient new directors

Tempest Announces Successful End-Of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

New major risk - Share price stability

New major risk - Financial position

CEO, President & Director recently bought US$74k worth of stock

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $205 million.

Tempest Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $205 million.

New major risk - Share price stability

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting

Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Price target increased by 26% to US$19.67

Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development

High number of new and inexperienced directors

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Tempest Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq

Tempest Therapeutics, Inc. Announces Executive Changes

Price target decreased by 18% to US$15.67

New major risk - Market cap size

Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

Price target increased by 16% to US$19.00

No independent directors

Tempest Therapeutics, Inc. Announces Executive Changes

Tempest Therapeutics GAAP EPS of -$0.79

Tempest Therapeutics Inc. Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors

Tempest Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

No independent directors

Tempest Therapeutics CEO Stephen Brady - Small Molecule Cancer Treatment

Director Brett I. Zbar has left the company

Director Keting Chu has left the company

Director Jiaxin Li has left the company

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies